Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40003153
Localisation
United Kingdom
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
16/11/2023
Statut
Classification
1.5°C
Année cible
2030
Statut
Targets set
Classification
1.5°C
Année cible
2045
Overall Net-Zero Target GSK commits to reach net-zero greenhouse gas emissions across the value chain by 2045 from a 2020 base year. Near-Term Targets GSK commits to reduce absolute scope 1 and 2 GHG emissions 80% by 2030 from a 2020 base year.* GSK also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, use of sold products and end of life treatment of sold products 80% within the same timeframe. *The target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks Long-Term Targets GSK commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2045 from a 2020 base year.* GSK also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, use of sold products, end of life treatment of sold products and investments 90% within the same timeframe. *The target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks
Statut
Targets setAnnée cible
2045
Statut
BA1.5 memberDate d'engagement
05/11/2020
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
GB00BN7SWP63
LEI
5493000HZTVUYLO1D793
Source : Science Based Targets initiative | Données publiques